Keloid Treatment Market Research Report - Global Forecast till 2030

Keloid Treatment Market Research Report: By Product (Elastic Wraps, Ointment), by Treatment (Radiation Therapy, Cry Therapy, Surgical Treatment, Laser Treatment, Laser Treatment, Interferon), by End-User (Hospitals and Others)—Forecast till 2030

ID: MRFR/Pharma/5340-HCR | February 2023 | Region: Global | 90 Pages         

Keloid Treatment Market Speak to Analyst Request a Free Sample

Keloid Treatment Market

Keloid Treatment Market is expected to register a CAGR of 3.30% and was valued at USD 1,172.1 Million.

Segmentation
By Product Elastic Wraps Ointment
By Treatment Radiation Therapy Cry Therapy Surgical Treatment Laser Treatment Laser Treatment Interferon
By End User Hospitals and Others
Key Players
Companies Profiled   Novartis AG    RXi Pharmaceuticals    Inc.    Sonoma Pharmaceuticals    Inc.    Bristol-Myers Squibb Company    Pacific World Corporation    Valeant Pharmaceuticals International    Inc.    Revitol Corporation    Avita Medical Limited    Sensus Healthcare    Perrigo Company plc.
Drivers
Market Driving Forces   Rapid rise in the technological scenario behind skin care products   Treatment type - Intralesional steroids injection
Request a Free Sample

Keloid Treatment Market Overview The keloid treatment market is expected to reach USD 1,172.1 Million by 2030 and is expected to increase at a CAGR of 3.30% during the forecast period 2022-2030. A keloid is a thickened scar that rises over the surrounding skin. It is usually pink or purple. Keloids are unevenly shaped scars that appear on the skin and grow in size over time. Keloids, unlike other scars, do not fade over time. According to the National Library of Medicine in the United States, keloid scarring affects people of all ages, although dark-skinned persons are more susceptible, with between 6% to 16% of African populations suffering from keloid skin disorders. Due to significant advancements in technology skincare products, the keloid treatment industry is likely to increase. The market is also rising as individuals become more aware of the various treatment methods and other items available to cure keloid. Additionally, increased spending on skincare products and services, as well as changing lifestyles, have all contributed to the Keloid Treatment Market's growth. However, the market is being driven by increasing awareness among patients, particularly females, about their looks. Clinics and hospitals are focused on the adoption of modern therapy alternatives as the demand for keloid treatment grows. Sensus Healthcare recently developed a superficial radiation therapy device to give better treatment with fewer side effects.

Key players:


Some of the key players in the keloid treatment market are Novartis AG, RXi Pharmaceuticals, Inc., Sonoma Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Pacific World Corporation, Valeant Pharmaceuticals International, Inc., Revitol Corporation, Avita Medical Limited, Sensus Healthcare, Perrigo Company plc.


Market Segmentation:


The keloid treatment market is segmented into product type, treatment, and end-users.


Based on product type the market is segmented into elastic wraps, spray, ointment, creams, oils, topical gels & gel sheets.


Based on treatment market for keloid has been segmented into ligature, radiation therapy, cry therapy, surgical treatment, laser treatment, steroid injections, corticosteroid injections (intralesional steroids), silicone gel or sheeting, occlusive dressing, compression therapy, and interferon. Corticosteroid injections treatment segments lead the keloid treatment market as this treatment is used in combination with other therapies. Intralesional steroids injection is considered to be the second largest segment of treatment type that drives market.


On the basis of end-users, the keloid treatment market is segmented into dermatology clinics, hospitals, ambulatory surgical centers. Hospital is expected to hold the largest share in the segment market of end-users as most doctors prefer radiation therapy which has reported safe and effective use of radiation to treat keloid.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European keloid treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa has been segmented into the Middle East and Africa.


Regional Market Summary


Geographically, North America dominates the keloid treatment market and is expected to continue to dominate the market throughout the forecast period. Clinics in North America are adopting advanced technologies for the treatment of keloid. Development of new technologies, product, alternative treatment and high disposable income of people in this region is responsible for the rapid growth of the keloid treatment market in this region.


Europe is the second largest market in the globe owing to the increasing awareness among people, favorable reimbursement scenario for skin treatment, increasing government expenditure for skin care product, the presence of disposable income and increasing demand for the cosmetic product.


Asia-Pacific is anticipated to be the fastest growing market owing to the growing prevalence of skin caries, increased focus on appearance and aesthetic in the developing countries, rising population, increasing disposable income, and growing healthcare expenditure are anticipated to increase the keloid treatment market in Asia-Pacific.   


The Middle East & Africa is expected to account for the lowest market share in the keloid treatment market due to low development, lack of technical knowledge, and poor medical facilities in developing economies in this region.


Global Keloid Treatment Market Share (%), by Region, 2017 Keloid Treatment Market Share


Source: Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), American College of Prosthodontists


Market of Keloid Treatment, by Product Type



  • Elastic Wraps

  • Sprays

  • Ointment

  • Creams

  • Oils

  • Topical Gels & Gel Sheets


Market of Keloid Treatment, by Treatment



  • Ligature

  • Radiation Therapy

  • Cry Therapy

  • Surgical Treatment

  • Laser Treatment

  • Steroid Injections

  • Corticosteroid injections (intralesional steroids)

  • Silicone gel or sheeting

  • Interferon


Market of Keloid Treatment, by End User



  • Dermatology clinics

  • Hospitals

  • Ambulatory surgical centers

  • Others


Market of Keloid Treatment, by Region



  • Americas


    • North America


      • US

      • Canada


    • South America




  • Europe


    • Western Europe


      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe


    • Eastern Europe




  • Asia Pacific


    • Japan

    • China

    • India

    • Australia

    • Republic of Korea

    • Rest of Asia Pacific




  • Middle East & Africa


    • Middle East

    • Africa



Recent Development


POETYK PSO-2, the second pivotal Phase III clinical trial assessing deucravacitinib, a new, selective tyrosine kinase 2 inhibitor for the treatment of patients with moderate to severe plaque psoriasis, was published in February 2021 by Bristol Myers Squibb Company. POETYK PSO-2 looked at deucravacitinib 6 mg once a day and found that it met both co-primary objectives, with considerably more patients reaching Psoriasis Area and Severity Index (PASI 75). JUBLIA (efinaconazole) topical solution for the treatment of onychomycosis was approved by the US Food and Drug Administration (FDA) in April 2020 for Bausch Health Companies Inc. and its dermatology business Ortho Dermatologics in Keloid Treatment Market

Intended Audience



  • Manufacturers and Suppliers

  • Dermatology Hospitals and Clinics

  • Dermatology laboratories and associations

  • Research and development centers



Report Scope:

Report Attribute/Metric Details
  Market Size   USD 1,172.1 Million
  CAGR   3.80%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Product, Treatment, End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Novartis AG, RXi Pharmaceuticals, Inc., Sonoma Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Pacific World Corporation, Valeant Pharmaceuticals International, Inc., Revitol Corporation, Avita Medical Limited, Sensus Healthcare, Perrigo Company plc.
  Key Market Opportunities   Increasing research & development investments by industry players
  Key Market Drivers

  • Rapid rise in the technological scenario behind skin care products
  • Treatment type - Intralesional steroids injection


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The global keloid market is expected to reach a valuation of USD 1,172.1 Million by 2030.

    The market is expected to exhibit a strong 3.30% CAGR over the forecast period from 2022-2030.

    The rapid rise in the technological scenario behind skin care products is the major driver for the global keloid treatment market.

    North America is the dominant regional market for keloid treatment.

    Leading players in the keloid treatment market include Valeant, RXi Pharmaceuticals, Novartis, and Pacific World Corporation, among others.